AVEO Oncology (AVEO) – Globe Newswire
-
LG Chem Completes Acquisition of AVEO Oncology
-
AVEO Oncology Stockholders Approve Acquisition by LG Chem
-
AVEO Oncology Stockholders Approve Acquisition by LG Chem
-
AVEO Oncology Reminds Stockholders to Vote “FOR” All-Cash Transaction with LG Chem in advance of the Special Meeting of Stockholders
-
AVEO Oncology Reports Third Quarter 2022 Financial Results
-
LG Chem to Acquire AVEO Oncology for $15.00 Per Share in Cash
-
LG Chem to Acquire AVEO Oncology for $15.00 Per Share in Cash
-
U.S. Patent & Trademark Office Allows AVEO Oncology’s Patent Application Covering Use of FOTIVDA® for the Treatment of Refractory Advanced Renal Cell Carcinoma
-
AVEO Oncology Announces Participation at the Cantor Fitzgerald Oncology & HemOnc Conference
-
AVEO Oncology Announces Participation at Investor Conferences in September
-
AVEO Oncology Reports Second Quarter 2022 Financial Results
-
AVEO Oncology to Announce Second Quarter 2022 Financial Results on August 4, 2022
-
AVEO Oncology Announces Clinical Trial Collaboration and Supply Agreement with Eli Lilly and Company for ERBITUX® (cetuximab) in North America to Evaluate Ficlatuzumab and Cetuximab in Patients with
-
AVEO Oncology Announces Updated NCCN Clinical Practice Guidelines Elevate FOTIVDA® (tivozanib) to Category 1 Treatment for Relapsed or Refractory Advanced (R/R) Renal Cell Carcinoma (RCC) Patients
-
AVEO Oncology Presents Three Posters for Tivozanib at the 2022 ASCO Annual Meeting
-
AVEO Oncology Announces Participation at the H.C. Wainwright Global Investment Conference
-
AVEO Oncology Reports First Quarter 2022 Financial Results
-
AVEO Oncology to Announce First Quarter 2022 Financial Results and Host Conference Call and Webcast on May 5, 2022
-
AVEO Oncology Reports Full Year and Fourth Quarter 2021 Financial Results
-
AVEO Oncology to Announce Full Year 2021 Financial Results and Host Conference Call and Webcast on March 14, 2022
-
AVEO Oncology to Present Positive New Long-Term PFS Data from Phase 3 TIVO-3 Study of FOTIVDA® (tivozanib) in Third- and Fourth-Line Renal Cell Carcinoma
-
AVEO Oncology Announces Participation at the 11th Annual SVB Leerink Global Healthcare Conference
-
AVEO Oncology Highlights Recent Progress and 2022 Outlook
-
AVEO Oncology Announces Clinical Trial Collaboration and Supply Agreement with Merck KGaA, Darmstadt, Germany to Evaluate Ficlatuzumab and ERBITUX® (cetuximab) in Patients with Recurrent or Metastati
-
AVEO Oncology Announces Participation at the H.C. Wainwright Virtual BioConnect 2022 Conference
Back to AVEO Stock Lookup